Current applications for nicardipine in invasive and interventional cardiology

Journal of Invasive Cardiology

Volumn 16, Issue 8, 2004, Pages 428-432

  Fischell, Tim A ^a,b   Maheshwari, Alok ^a  

^a Borgess Heart Institute   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Calcium channel blockers; Coronary artery bypass graft; Nicardipine; No reflow; Percutaneous coronary interventions; Vasodilators

Indexed keywords

ADENOSINE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FIBRINOGEN RECEPTOR ANTAGONIST; NICARDIPINE; NICORANDIL; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; NITROPRUSSIDE SODIUM; PAPAVERINE; VASODILATOR AGENT; VERAPAMIL;

CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HEART CATHETERIZATION; HUMAN; HYPERTENSION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MORBIDITY; NONHUMAN; REVIEW; ROTATIONAL ATHERECTOMY; SIDE EFFECT; SURGICAL MORTALITY; TREATMENT INDICATION; VASOCONSTRICTION; VASODILATATION;

ATHERECTOMY, CORONARY; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY BYPASS; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRAVENOUS; NICARDIPINE; POSTOPERATIVE COMPLICATIONS; VASOCONSTRICTION;

EID: 4143055025     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Hardman JG, Limbird LE (eds). Goodman's & Gilman's The Pharmacological Basis of Therapeutics. 9th Ed. New York, New York: McGraw-Hill Publishers, 1996.
2. Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977;298:267.
3. Bayer R, Rodenkirchen R, Kaufmann R, et al. The effects of nifedipine on contraction and monophasic action potential of isolated cat myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977;301:29.
4. Kaltenbach M, Shulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol 1979;44:832.
5. Henry PD, Schuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia: Analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 1979;44:817.
6. Kitakaze M, Asanuma H, Takashima S, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000;101:311.
7. Casolo GC, Balli E, Poggesi L, Gensini GF. Increase in number of myocardial ischemic episodes following nifedipine administration in two patients: Detection of silent episodes by Holter monitoring and role of heart rate. Chest 1989;95:541.
8. Clarke B, Grant D, Patmore L. Comparative calcium entry blocking properties of nicardipine, nifedipine and PY-108-68 on cardiac and vascular smooth muscle. Br J Pharmacol 1983;79:333P.
9. Alps BJ, Calder C, Wilson A. Nicardipine in models of myocardial infarction. Br J Clin Pharmacol 1985;20(Suppl 1):29S-49S.
10. Alps BJ, Hass WK. The potential beneficial effect of nicardipine in a rat model of transient forebrain ischemia. Neurology 1987;37:809-814.
11. Nakaya H, Kanno M. Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. Arzneimittel-Forschung 1982;32:626-629.
12. Michel AD, Whiting RL. Cellular action of nicardipine. Am J Cardiol 1989;64:3H-7H.
13. Cardene IV [package insert]. Edison, NJ: ESP Pharma, Inc.: 2003.
14. Whiting RL, Dow RJ, Graham DJ, Mroszczak EJ. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology 1990;41(11 Pt 2):987-991.
15. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 1989;64:8H-15H.
16. Kaufmann P, Vassalli G, Utzinger U, Hess OM. Coronary vasomotion during dynamic exercise: Influence of intravenous and intracoronary nicardipine. J Am Col Cardiol 1995;26:624-631.
17. Henry PD. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol 1980;46:1047-1058.
18. Singh BN, Josephson MA. Clinical pharmacology, pharmacokinetics and hemodynamic effects of nicardipine. Am Heart J 1990;119(2 Pt 2):427-434.
19. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656.
20. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729.
21. Hearse DJ, Bolli R. Reperfusion induced injury. Manifestations, mechanisms and clinical relevance. Cardiovasc Res 1992;26:101.
22. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: Which comes first? Circulation 1980;62:945.
23. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993.
24. Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794.
25. Gregorini L, Marco J, Kozakova M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary artery stenting in patients with acute myocardial infarction. Circulation 1999;99:482.
26. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994;89:2514.
27. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202.
28. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
29. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995;75:849-850.
30. Abbo KM, Dooris M, Glaziet S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
31. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions. Comparison of intracoronary verapamil and nitro-glycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
32. Jalinous F, Mooney JA, Mooney MR. Pretreatment with intracoronary diltiazem reduces non-Q wave myocardial infarction following directional atherectomy. J Invas Cardiol 1997;9:270-273.
33. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-1199.
34. McIvor ME, Undemir C, Lawson J, Reddinger J. Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn 1995;35:287-291; discussion, 92-93.
35. Jang YH, Kim JM. Nicardipine augments local myocardial perfusion after coronary artery reperfusion in dogs. J Korean Med Sci 2003;18:23-26.
36. Lambert CR, Hill JA, Nichols WW, et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985;55:652-656.
37. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 1989;64:8H-15H.
38. Terris S, Bourdillon PD, Cheng DT, Pitt B. Direct cardiac and peripheral vascular effects of intracoronary and intravenous nifedipine. Am J Cardiol 1986;58:25-30.
39. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invas Cardiol 2000;12:80-85.
40. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: Results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invas Cardiol 2002;14:299-302.
41. Fischell TA, Lauer MA. Prevention and management of "no-reflow" during coronary interventions. In: Nissen S, Popma J, Kern M (eds). Cardiac Catheterization and Interventional Self-Assessment Program (CathSap II). Bethesda, Maryland: American College of Cardiology Foundation: 2001.
42. Carpentier A, Guermonprez JL, Deloche A, et al. The aorta-to-coronary radial artery bypass graft. A technique avoiding pathological changes in grafts. Ann Thorac Surg 1973;16:1111-1121.
43. Chamior-Clerc P, Copie X, Renaud JF, et al. Comparative reactivity and mechanical properties of human isolated internal mammary and radial arteries. Cardiovasc Res 1998;37:811-819.
44. Curtis JJ, Stoney WS, Alford WC Jr., et al. Intimal hyperplasia: A cause of radial artery aortocoronary bypass graft failure. Ann Thorac Surg 1975;20:628-635.
45. Acar C, Jebara VA, Portoghese M, et al. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg 1992;54:652-659.
46. Turlapaty P, Vary R, Kaplan JA. Nicardipine, a new intravenous calcium antagonist: A review of its pharmacology, pharmacokinetics and perioperative applications. J Cardiothorac Anesth 1989;3:344-355.
47. He GW, Yang CQ. Comparative study on calcium channel antagonists in the human radial artery: Clinical implications. J Thorac Cardiovasc Surg 2000;119:94-100.
48. Cable DG, Caccitolo JA, Pearson PJ. New approaches to prevention and treatment of radial artery graft vasospasm. Circulation 1998;98(Suppl):II-15-II- 22.
49. Radermecker MA, Grenade T, Cao-Thian SK, et al. Nicardipine protocol for CABG using the radial artery clinical and angiographic data. Acta Chir Belg 2001;101:185-189.
50. Goldberg ME, Clark S, Joseph J, et al. Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J 1990;119(2 Pt 2):446-450.
51. Goldberg ME and the IV Nicardipine Study Group. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. Chest 1991;99:393-398.
52. Halpern NA, Alicea M, Krakoff LR, Greenstein R. Postoperative hypertension: A prospective, placebo-controlled, randomized, double-blind trial, with intravenous nicardipine hydrochloride. Angiology 1990;41(11 Pt 2):992-1004.
53. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: A multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 1992;20:1637-1643.
54. Halpern NA, Sladen RN, Goldberg JS, et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit Care Med 1990;18:950-955.
55. Wallin JD, Fletcher E, Ram CV, et al. Intravenous nicardipine for the treatment of severe hypertension. A double-blind, placebo-controlled multicenter trial. Arch Internal Med 1989;149:2662-2669.
56. van Wezel HB, Koolen JJ, Visser CA, et al. The efficacy of nicardipine and nitroprusside in preventing poststernotomy hypertension. J Cardiothorac Anesth 1989;3:700-706.
57. Combes P, Durand M. Comparison of nicardipine and sodium nitroprusside in the treatment of hypertension after coronary bypass surgery (a pilot study). Acta Anaesthesiol Belg 1992;43:113-119.
58. David D, Dubois C, Loria Y. Comparison of nicardipine and sodium nitroprusside in the treatment of paroxysmal hypertension following aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1991;5:357-361.
59. Vecht RJ, Swanson KT, Nicolaides EP, et al. Comparison of intravenous nicardipine and nitroglycerin to control systemic hypertension after coronary artery bypass grafting. Am J Cardiol 1989;64:19H-21H.
60. Oh Y, Hong Y, Band S, Kwak Y. The comparison of sodium nitroprusside and nicardipine on postoperative hypertension in coronary artery graft surgery. Anesth Analg 2002;93:SCA75.